Potent and orally available inhibitor of VAP-1 (aka SSAO/AOC3; IC50 value 5 nM), inhibiting neutrophil rolling and tethering in the mouse cremaster model, and showing >500-fold selectivity for VAP-1/SSAO over all the related human amine oxidases. PXS 4728 diminishes lung inflammation in a variety of models indicating proof of concept for a novel therapeutic approach in respiratory diseases that are characterized by neutrophilic pattern of inflammation. PXS 4728 is in clinical trials for the treatment of cardiometabolic diseases like the liver-related disease Nonalcoholic Steatohepatitis (NASH).

KEYWORDS: PXS 4728A | supplier | VAP-1 inhibitor | PXS 4728 HCl | PXS4728 | CAS [1478364-68-9] | [1478364-40-7] | Mono-amines | VAP | Inhibitor | SSAO | AOC3 | neutrophil | adhesion molecules | VAP-1/SSAO | lung inflammation | COPD | airway | respiratory | steatohepatitis | NASH | liver disease | Semicarbazide Sensitive Amine Oxidase